News|Articles|March 9, 2023

Vetter Joins United Nations Global Compact

Author(s)Alivia Leon

Vetter has become a participant of the UN Global Compact Network.

Vetter announced on March 6, 2023 that is has become a participant of the UN Global Compact Network. The UN Global Compact was launched in 2000 and is the largest corporate initiative on sustainable business worldwide. More than 15,000 companies and 3000 non-profit organizations from over 160 countries have signed the initiative to date.

A main focus of the UN Global Compact is on the enforcement and implementation of human and employee rights, environmental protection, and the prevention of corruption. By becoming a participant, Vetter gains access to the large network of companies and organizations that are committed to the same corporate goals. Vetter will submit a publicly viewable annual progress report, which will serve as evidence of transparency and accountability.

"As a family-owned business in the healthcare sector, we bear great responsibility,” said Henryk Badack, senior vice president, technical service and internal project management, in a company press release. “And we believe in the power of cooperation. The UN Global Compact combines these two approaches very well and is also a strong commitment to shared values and goals across business sectors and national borders."

Source: Vetter


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.